Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?

Moreno-Fernández, Jesús; García-Seco, José Alberto; Segura, A; García-Seco, Fernando; Moreno, Pedro Jesus Rozas; Sánchez-Covisa, Miguel Aguirre

doi:10.1016/j.pcd.2019.05.006

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the condition of long-term hyperglycemia, the body of T2DM patients gradually presents inflammatory responses, and most diabetic patients also have dyslipidemia, which destroys vascular endothelial function of patients [16]. However, vascular endothelial function impairment is the basic pathological change of various complications in T2DM patients, which will lead to atherosclerosis and thrombosis [17]. NO and ET-1 are a pair of antagonistic vasoactive substances synthesized by vascular endothelial cells and can maintain vascular homeostasis.…”

Section: Groupsmentioning

confidence: 99%

Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus

Xianjuan Wang,

Kun He,

Jing Li

et al. 2024

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Materials and methods Clinical data90 patients with T2DM from October 2021 to February 2023 were selected. A control group and an observation group were established by the random number table method. In the control group, there were 26 males and 19 females, aged from 41 to 78 years with an average age of (59.67±5.31) years. The course of disease ranged from 6 months to 9 years, with an average of (2.58 ± 0.56) years. BMI ranges from 18.5 to 28.3 kg/m 2 , with an average of (23.01 ± 1.26) kg/m 2 . The observation group included 24

show abstract

Section: Groupsmentioning

confidence: 99%

Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus

Xianjuan Wang,

Kun He,

Jing Li

et al. 2024

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

show abstract

“…We used the search strategy and the same limitations, 662 studies were searched in the following databases, PubMed, 70 studies, Embase, 131 studies, Cochrane, 174 studies, and Web of Science, 280 studies, and finally, 7 studies were searched through other sources. According to the inclusion and exclusion criteria, 12 RCTs [17][18][19][20][21][22][23][24][25][26][27][28] were finally included.…”

Section: Literature Selection Process and Characteristic Of Studiesmentioning

confidence: 99%

“…3A). 11 RCTs, [12][13][14][15][16][17][19][20][21][22][23] including a total of 2651 patients, the decrease of FPG was more significant in the long-acting group (MD = −0.77, 95% CI [−1.01, −0.52], I 2 = 70%, P < .00001) (Fig. 3B).…”

Section: Primary Outcomementioning

confidence: 99%

Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis

Yuan,

Gao,

Hao

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) showed great value in treating nonalcoholic fatty liver disease (NAFLD). We aimed to compare the effectiveness of long-acting and short-acting GLP-1RAs on improving body weight and related metabolic parameters in patients with type 2 diabetes (T2DM) as a reference for the treatment of NAFLD with T2DM. Methods: We searched eligible randomized controlled trials (RCTs) in PubMed, Embase, Cochrane and web of science database until August 2023. The risk of bias of included RCTs were assessed by the Risk Assessment of Cochrane Review items. We mainly drew forest plots to compare the effects of long and short acting GLP-1 RAs using RevMan 5.4. Results: Twelve RCTs involving 2751 patients were included in our meta-analysis. Compared with short-acting GLP-1 RAs, the long-acting group was better in body weight (P < .00001, MD = −0.65, 95% confidence interval [CI] [−0.90, −0.40], I2 = 20%), and the same results in glycosylated hemoglobin (HbA1c) (P < .00001, MD = −0.43, 95% CI [−0.54, −0.33], I2 = 55%) and fasting plasma glucose (FPG) (P < .00001, MD = −0.77, 95% CI [−1.01, −0.52], I2 =70%). For the lipid parameters, long-acting drugs lowered cholesterol (TC) (P = .02, SMD = −0.19, 95% CI [−0.35, −0.03], I2 =57%) and low-density lipoprotein (LDL) (P = .02, SMD = −0.17, 95% CI [−0.33, −0.02], I2 =51%) more significantly compared with short-acting drugs. But treatment differences were not significant in triglycerides (TG) (P = .40, SMD = −0.05, 95% CI [−0.15, −0.06], I2 = 0%), and high-density lipoprotein (HDL) (P = .85, SMD = −0.01, 95% CI [−0.11, −0.09], I2 = 0%). Conclusion: Long-acting GLP-1RAs may be more promise than short-acting GLP-1RAs in improving weight and related metabolic parameters.

show abstract

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucoselowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular and renal benefits. Current guidelines recommend their use in patients with type 2 diabetes (T2D) at high risk of or with established cardiovascular disease (CVD), regardless of glycaemic control, with lifestyle modification and metformin. However, several studies have recently highlighted the limited number of patients with T2D benefiting from these medications worldwide. Given the huge burden of CVD among patients with T2D, efforts should be made to bring clinical practice closer to expert guidelines. This review describes the current situation of GLP-1 RA use in Spain and the reasons behind the gap between guidelines and realworld practice and suggests possible solutions.

show abstract

Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?

Cited by 5 publications

References 18 publications

Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus

Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus

Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

Contact Info

Product

Resources

About